Items Tagged ‘treatment’

July 23, 2018

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

By

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included […]

View full entry

Tags: Acute Myeloid Leukemia, IGH1 Mutation, Leukemia, News, refractory, relapsed, Tibsovo, treatment


July 19, 2018

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

By

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and […]

View full entry

Tags: EGFR, Head and Neck Cancer, News, Nimotuzumab, treatment


June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News, Pancreatic Cancer, treatment


June 6, 2018

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer

By

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall 43% of patients achieved a complete response and Vicinium appears to represent an emerging treatment option. About Vicinium Vicinium, […]

View full entry

Tags: BCG, Bladder Cancer, News, Non muscle invasive, treatment, Vicinium


June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori


May 21, 2018

FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches

By

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million people in the U.S. yet they are still a poorly recognized and under-diagnosed disease. In 2018, the number of migraine-specific treatments available in the US will double […]

View full entry

Tags: Aimovig, General, Headaches, Migraine, News, prevention, treatment


May 4, 2018

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer

By

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative intent therapy. About Muscle Invasive Bladder Cancer Bladder cancer is the fifth most common neoplasm in industrialized countries, affecting […]

View full entry

Tags: Bladder Cancer, GemRIS, Muscle invasive, News, Taris, treatment


April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


April 10, 2018

Managing Side Effects From EGFR Inhibitors

By

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs and these cause similar side effects. The EGFR pathway is a normal biologic pathway found in […]

View full entry

Tags: cetuximab, Colon Cancer, diarrhea, EGFR inhibitors, erbitux, erlotinib, gefitinib, Head and Neck Cancer, iressa, Lung Cancer, News, Panutumamab


April 9, 2018

Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer

By

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. About Rubraca® Rubraca® is […]

View full entry

Tags: cancer treatment, News, ovarian, Ovarian Cancer, poly ADP-ribose polymerase (PARP) inhibitor, recurrent, Rubraca, treatment


March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News, Pancreatic Cancer, Precision Cancer Medicine, treatment


February 26, 2018

Keytruda Improves Survival of Advanced Bladder Cancer

By

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary Cancer Symposium.1 About Bladder Cancer Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, treatment


February 19, 2018

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer

By

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada (Apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).1  There were previously no FDA-approved treatments for […]

View full entry

Tags: Apalutamide, Erleada, News, non-metastatic castration-resistant prostate cancer, Prostate Cancer, rising psa, treatment


February 13, 2018

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer

By

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from […]

View full entry

Tags: Breast Cancer, CDK4/6 inhibitor, kisqali, News, ribociclib, treatment